Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies

2782 - Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC – Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial.

Date

29 Sep 2019

Session

Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies

Presenters

Solange Peters

Citation

Annals of Oncology (2019) 30 (suppl_5): v591-v601. 10.1093/annonc/mdz259

Authors

S. Peters1, E. Felip2, U. Dafni3, A. Tufman4, M. Guckenberger5, A. Irigoyen6, E. Nadal7, A. Becker8, H. Vees9, M. Pless10, A. Martinez-Marti2, M. Lambrecht11, N. Andratschke5, Z. Tsourti12, A. Piguet13, H. Roschitzki-Voser13, M. Rabaglio-Poretti13, R.A. Stahel14, J.F. Vansteenkiste15, D. De Ruysscher16

Author affiliations

  • 1 Department Of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 - Lausanne/CH
  • 2 Institute Of Oncology (vhio), Vall d'Hebron University Hospital, Barcelona/ES
  • 3 Statistics, Frontier Science Foundation-Hellas & National and Kapodistrian University, Athens/GR
  • 4 German Center For Lung Research, Ludwig Maximilian University of Munich (LMU), Medizinische Klinik and Poliklinik V, Munich/DE
  • 5 Department For Radiation Oncology, University Hospital, Zürich/CH
  • 6 Department Of Medical Oncology, Hospital Virgen De La Salud, Toledo/ES
  • 7 Catalan Institute Of Oncology, Department Of Medical Oncology, IDIBELL L'Hospitalet, Barcelona/ES
  • 8 Department Of Respiratory Diseases, Amsterdam University Medical Center, Amsterdam/NL
  • 9 Radiation Oncology, Clinic Hirslanden, Zurich/CH
  • 10 Medical Oncology, Cantonal Hospital Winterthur, Winterthur/CH
  • 11 Department Of Radiotherapy-oncology, University Hospital KU, Leuven/BE
  • 12 Statistics, Frontier Science Foundation-Hellas, Athens/GR
  • 13 Coordinating Office, European Thoracic Oncology Platform (ETOP), 3008 - Bern/CH
  • 14 Department Of Haematology And Oncology, University Hospital Zürich, Zürich/CH
  • 15 Department Of Respiratory Diseases, University Hospital KU, Leuven/BE
  • 16 Department Of Radiation Oncology, Maastro Clinic, Maastricht/NL
More

Resources

Abstract 2782

Background

NICOLAS is a single-arm phase II trial in stage III NSCLC. The safety analysis has earlier provided evidence that nivolumab administration concurrently to chemo-radiotherapy (CRT) is safe and tolerable, with respect to the occurrence of clinically relevant (grade > =3) pneumonitis. According to a hierarchical design, efficacy evaluation was planned provided the safety conclusion regarding pneumonitis was reached.

Methods

Primary efficacy endpoint is the 1-year (1y) progression-free survival (PFS) rate. Patients (pts) received 3 cycles of platinum-based chemotherapy and concurrent RT (66Gy/33fractions). Nivolumab started concurrently with CRT (360mg, Q3W) and subsequently continued as monotherapy consolidation (480mg, Q4W). The aim was a 1y PFS rate improvement of at least 15%, from 45% to 60%. A sample size of 74 evaluable pts provides power 83%, for testing this efficacy hypothesis, using an exact binomial test at 1-sided alpha 5%.

Results

PFS is evaluated in 79 pts assigned to concurrent treatment. Two pts died before starting treatment. Up to 20 March 2019, the median follow-up is 16.4 months (m) (Interquartile Range: 11-20 m). The majority of pts are male (67%), former smokers (68%), of median age 62 years. The ECOG performance status at enrolment, is PS 0/1 for 48%/52% of pts, while 64% present with stage IIIb. The Kaplan-Meier estimate of the 1y PFS rate is 54% (95% CI: 41-65%), with median PFS 12.4 m (95% CI: 9, Not estimable). Currently, 62 pts have either been followed beyond 1y or had a PFS event up to that timepoint. The 1y overall survival (OS) rate is 79% (95% CI: 68-87%) while median OS is not reached yet. The most frequent adverse events (AEs) were anaemia, fatigue and pneumonitis. No unexpected AEs or increased toxicities were observed.

Conclusions

The 1y-PFS estimate will be final when all pts have reached 1y after enrolment, in August 2019. A promising result on the PFS rate, coupled with the already reported evidence that the addition of nivolumab to CRT is safe and tolerable, would further support concurrent immunotherapy and CRT in locally advanced NSCLC.

Clinical trial identification

NCT02434081.

Editorial acknowledgement

Legal entity responsible for the study

European Thoracic Oncology Platform (ETOP).

Funding

Bristol-Myers Squibb.

Disclosure

S. Peters: Honoraria (self): AbbVie; Honoraria (self): Amgen; Honoraria (self): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Biocartis; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Clovis; Honoraria (self): Daiichi Sankyo; Honoraria (self): Debiopharm; Honoraria (self): Eli Lilly; Honoraria (self): Roche; Honoraria (self): Foundation Medicine; Honoraria (self): Illumina; Honoraria (self): Janssen; Honoraria (self): Merck Sharp & Dohme; Honoraria (self): Merck Serono; Honoraria (self): Merrimack; Honoraria (self): Novartis; Honoraria (self): Pharma Mar; Honoraria (self): Pfizer; Honoraria (self): Regeneron; Honoraria (self): Sanofi; Honoraria (self): Seattle Genetics; Honoraria (self): Takeda. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KGaA; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy: Blue print medicines; Advisory / Consultancy: Celgene; Advisory / Consultancy: Quadrant health; Advisory / Consultancy: Janssen ; Advisory / Consultancy: Medscape; Advisory / Consultancy: Touchtime. A. Tufman: Advisory / Consultancy: BMS; Advisory / Consultancy: Takeda; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Celgene. M. Guckenberger: Advisory / Consultancy: AstraZeneca; Research grant / Funding (self): Varian. E. Nadal: Advisory / Consultancy: BMS. M. Pless: Advisory / Consultancy: AbbVie; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy: Eisei; Advisory / Consultancy: Janssen; Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Takeda. A. Martinez-Marti: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy: MSD Oncology. M. Lambrecht: Advisory / Consultancy: AstraZeneca. N. Andratschke: Honoraria (self): AstraZeneca; Research grant / Funding (self): Brainlab. R.A. Stahel: Honoraria (self): AbbVie; Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (self): MSD; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self), Research grant / Funding (self): Roche; Honoraria (self): Takeda; Research grant / Funding (self): BMS; Research grant / Funding (self): Genentech. J.F. Vansteenkiste: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Apotex. D. De Ruysscher: Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Celgene; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Genentech; Research grant / Funding (institution): Philips; Research grant / Funding (institution): Varian. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.